Yuhan Corporation acquires approval of clinical trial for cancer immunotherapy for first time in Korea

Published: 2018-02-06 16:13:57

Updated: 2018-02-06 16:13:57

ImmuneOncia(CEO Kwang-Ho Jung), a subsidiary of Yuhan Corporation, announced that the company has acquired approval of the Phase I clinical trial plan for IMC-011, a cancer immunotherapy, from the Ministry of Food and Drug Safety on 1 February. It was the first one which acquired approval as a Korean new drug that is PD-1 and PDL1 checkpoint signaling inhibitor.

ImmuneOncia which starts to dev...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.